Strategic Partnerships Position AlphaVax as a co-development or licensing partner for CMV and pandemic influenza vaccines, leveraging its robust B and T cell immune responses and biodefense programs to engage large pharma, biotech partners, and government agencies seeking early-stage platforms.

Platform Licensing License the alphavaccine vector platform for infectious disease and cancer programs, highlighting grant-supported and collaborator-supported work to de-risk early development and attract partners across collaboration and licensing deals.

Development Outsourcing With a lean team, pursue partnerships for clinical development, regulatory affairs, and early-phase trial management to accelerate timelines and reduce internal resource strain for AlphaVax.

Manufacturing Partnerships Explore contract manufacturing and fill-finish collaborations with CDMOs to provide scalable GMP production for influenza, CMV, and biodefense candidates, enabling smoother progression to later-stage trials.

Funding Opportunities Capitalize on grant and collaboration channels to secure non-dilutive funding, targeting biodefense and public health programs to broaden the pipeline and attract strategic partners.